FERRING-INTERNATIONAL
9.1.2017 14:02:20 CET | Business Wire | Press release
Ferring Pharmaceuticals is partnering with Intralytix, Inc to develop and commercialise bacteriophage-based treatments for conditions associated with the presence of pathogenic bacteria or dysbiosis of the microbiome.
The human body is host to trillions of microbes, bacteria, virus and fungi. This vast and complex microbial community is known as the microbiota. The collective name for all of the genes in the microbiota is the microbiome.
Bacteriophages are a normal part of the microbiota. These virus-like organisms have evolved naturally to target and destroy specific bacteria. They have significant potential compared to antibiotics to treat bacterial infections without affecting beneficial bacteria, such as the normal gut flora, to fine-tune the human microbiome and to address the growing issue of antibiotic resistance.
“Rapidly evolving science is uncovering the central role that the microbiome plays in human health and disease,” said Per Falk, Executive Vice President and Chief Scientific Officer, Ferring Pharmaceuticals. “Ferring is committed to advancing microbiome research in order to develop innovative new ways to diagnose, treat and prevent disease, and to address urgent unmet needs.”
Bacterial resistance to antibiotics is an increasingly serious threat to global public health1 and a key focus of the collaboration will be on developing treatments for multi-drug resistant bacteria.
"Phage-based anti-bacterial treatments are rapidly emerging as a safe, effective and natural way to help maintain healthy microbiota,” said Alexander Sulakvelidze, Vice President for Research and Development and Chief Scientific Officer of Intralytix. “We are delighted to be expanding our collaboration with Ferring. Together, we can enhance product development, and bring benefits to patients more quickly.”
Ferring announced an initial collaboration with Intralytix on a bacteriophage-based therapy for inflammatory bowel disease (IBD) in July 2015. By broadening the collaboration, Ferring and Intralytix will now jointly investigate bacteriophage-based drugs to regulate the microbiome of the female reproductive tract, oral cavity, and skin, in addition to the gut.
ENDS
About the Microbiota
The human body is host to trillions of microbes, bacteria, virus and fungi. This vast and complex microbial community is known as the microbiota. The microbiota can be considered a “new organ” which actually constitutes 2 kg of the body. An estimated 80 % of its components have not yet been cultivated.
About the Microbiome
Each of the different microorganisms in the microbiota has its own unique set of genes. The collective name for all of the genes in the microbiota is the microbiome. Rapidly evolving science has uncovered a central role of the microbiome in human health and disease.
About Bacteriophages
Bacteriophage literally means ‘bacteria-eater’, taken from the Greek ‘phagein’ meaning "to eat". Bacteriophages are the most abundant microorganisms on earth and have evolved naturally to target and destroy specific bacteria. They are currently being investigated as a possible therapy against multi-drug-resistant strains of many bacteria.
About Ferring Pharmaceuticals
Headquartered in Switzerland, Ferring Pharmaceuticals is a research-driven, specialty biopharmaceutical group active in global markets. The company identifies, develops and markets innovative products in the areas of reproductive health, urology, gastroenterology, endocrinology and orthopaedics. Ferring has its own operating subsidiaries in nearly 60 countries and markets its products in 110 countries. To learn more about Ferring or its products please visit www.ferring.com .
About Intralytix, Inc.
Intralytix, Inc. is a privately-held company headquartered in Baltimore, Maryland. The company is the world’s leader in bacteriophage technology, and was the first company in the world to receive FDA-approval for a phage-based product for food safety applications. Intralytix currently has the largest in the world portfolio of phage-based products on commercial markets. The company holds several bacteriophage technology-related patents, including two U.S. patents (and additional patents pending) on the use of bacteriophages for fine tuning human or animal microbiome by using phage to reduce or eliminate bacterial colonization (US 7,459,272 B2 and US 8,003,323 B2). To learn more about Intralytix, Inc. or its products please visit www.intralytix.com
1 WHO Antimicrobial Fact sheet 2016 : http://www.who.int/mediacentre/factsheets/fs194/en/
View source version on businesswire.com: http://www.businesswire.com/news/home/20170109005710/en/
Contact:
Ferring Pharmaceuticals
Lindsey Rodger
Tel. +41 58 451
40 23
lindsey.rodger@ferring.com
or
Intralytix
Alexander
Sulakvelidze
Tel. +1 410 625 2533
asulakvelidze@intralytix.com
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Miro Takes Aim at the Gap Between AI Potential and Organizational Reality19.5.2026 16:00:00 CEST | Press release
At Canvas 26, Miro establishes its AI platform as the connective layer of the modern AI ecosystem — bringing together teams, agents, and the tools they already work in to turn individual AI productivity into organization-wide transformation Miro®, the AI Innovation Workspace for teams, has announced new innovations across its AI platform, reinforcing its position as the collaboration layer where people, context, and agents from every function converge to solve hard problems, make better decisions, and build the right thing faster. Major upgrades to Miro’s agentic AI tools — including Sidekicks and Flows — alongside new Connectors, help customers close the gap between individual AI productivity and organization-wide transformation. AI is reshaping the pace of work, but often teams are not realising the benefits. In many organizations, a gap has emerged between what individuals can now do and what companies can harness. The reason? Collaboration has fractured. Teams have moved from one m
Wolters Kluwer Medi-Span Selected to Provide Personalized Medication Decision Support at The Christie NHS Foundation Trust19.5.2026 15:30:00 CEST | Press release
Roll-out at largest EU cancer center marks first Medi-Span NHS implementation Wolters Kluwer Health has implemented its industry-leading medication decision support (MDS) solution, Medi-Span®, at the world-renowned specialist oncology center, The Christie NHS Foundation Trust. “The Christie is recognized globally for its excellence and commitment to delivering exceptional patient care,” says Israel Armstrong, Vice President for Medi-Span International at Wolters Kluwer Health. “We’re proud that our first Medi-Span implementation in the NHS should be with such a prestigious institution. We look forward to more collaborations that help streamline processes further and help clinical teams make the most highly informed decisions.” The Christie is a leading expert in cancer care, research and education and is the largest single-site cancer center in Europe. The Christie treats more than 60,000 patients a year and is the first facility in the UK to be accredited as a comprehensive cancer cen
Torq Acquires Jit to Unleash the First Enterprise AI SOC Context Graph—and Rewrite the Future of SecOps19.5.2026 15:00:00 CEST | Press release
With Jit Acquisition, Torq Catapults Enterprise SOCs Into a New Realm of Detailed Contextual Investigations That Drive Precision Decision-Making Torq, the established agentic security operations leader, today announced the acquisition of Jit, the Boston-based AI Context Graph cybersecurity pioneer. This move marks a dramatic leap forward for the Torq AI SOC Platform by ensuring agentic investigations are precisely informed via organization-specific contextual data. This shift redefines agentic reasoning, moving beyond static facts such as users, devices and their relationships, to prioritize live, dynamic contextual data overlaid on top, including business drivers, and the real-time state of the enterprise. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260519044833/en/ Instead of acting on fragmented data or having investigations triggered by a single alert, Torq AI operates with a unified, continuously-updated, contextual
Nine in 10 Firms Fear In-House Systems Can’t Keep Pace with Executive Pay Demands19.5.2026 15:00:00 CEST | Press release
89% of senior HR, rewards, and compensation leaders say in-house technology cannot keep pace with executive compensation demands80% report increased participation in incentive schemes over the past three years66% identify reliance on multiple service providers as a key barrier to maintaining accurate and consistent data Managing executive compensation is a growing challenge for financial services firms, with nearly nine in 10 (89%) saying their in-house technology can’t keep pace with demand. New research by CSC, the leading provider of business administration and compliance solutions, shows that rising complexity, regulatory pressure, and expanding global participation place increasing strain on internal systems and teams.1 CSC surveyed 300 senior HR, rewards, and compensation leaders across Europe, Asia Pacific, and North America working in private markets, asset management, insurance, and investment banking. The report, The Future of Reward in Financial Services: Executive Compensat
Tacton Appoints Manufacturing Technology Leader Mike DiTullio to Board of Directors19.5.2026 15:00:00 CEST | Press release
Former PTC President & COO brings decades of experience serving complex manufacturers and scaling global commercial organizations as Tacton advances growth in North America and EMEA. Tacton, a global leader in Configure, Price, Quote (CPQ) solutions for manufacturers of complex products, today announced the appointment of Mike DiTullio to its Board of Directors. DiTullio is an enterprise software executive with more than three decades of experience working with complex manufacturers. He joins at a pivotal moment in the company’s evolution as Tacton expands beyond CPQ to deliver the Buyer-Centric Smart Factory, a connected approach that unites buyer engagement, engineering, and order fulfillment into a single intelligent system. DiTullio spent 26 years at PTC, most recently as President and Chief Operating Officer, wherehe worked closely with leading manufacturers to transform how they design, sell, and deliver complex products. In that role, he led global commercial operations across s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom